var data={"title":"Ribavirin (systemic): Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Ribavirin (systemic): Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/791139?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=ribavirin-systemic-patient-drug-information\" class=\"drug drug_patient\">see &quot;Ribavirin (systemic): Patient drug information&quot;</a> and <a href=\"topic.htm?path=ribavirin-systemic-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Ribavirin (systemic): Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45623465\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Appropriate use (oral):</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Ribavirin monotherapy is not effective for the treatment of chronic hepatitis C virus (HCV) infection and should not be used alone for this indication.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Hemolytic anemia (oral):</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">The primary clinical toxicity of ribavirin is hemolytic anemia, which may result in worsening of cardiac disease and lead to fatal and nonfatal myocardial infarctions (MIs). Do not treat patients with a history of significant or unstable cardiac disease with ribavirin.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Pregnancy (oral):</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Significant teratogenic and/or embryocidal effects have been demonstrated in all animal species exposed to ribavirin. In addition, ribavirin has a multiple-dose half-life of 12 days, and it may persist in nonplasma compartments for as long as 6 months. Therefore, ribavirin therapy is contraindicated in women who are pregnant and in the male partners of women who are pregnant. Extreme care must be taken to avoid pregnancy during therapy and for 6 months after completion of treatment in women receiving ribavirin therapy and female partners of men who are taking ribavirin therapy. At least 2 reliable forms of effective contraception must be used during treatment and during the 6-month posttreatment follow-up period.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45623473\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Copegus [DSC];</li>\n      <li>Moderiba;</li>\n      <li>Moderiba 1200 Dose Pack;</li>\n      <li>Moderiba 800 Dose Pack;</li>\n      <li>Rebetol;</li>\n      <li>Ribasphere;</li>\n      <li>Ribasphere RibaPak;</li>\n      <li>RibaTab [DSC]</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45623474\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Ibavyr</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45623478\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Antihepaciviral, Nucleoside (Anti-HCV)</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45623529\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>\n        <i>Manufacturer&rsquo;s labeling:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Chronic hepatitis C monoinfection (in combination with peginterferon alfa-2b): Note:</b> Combination therapy with peginterferon alone is not recommended in HCV treatment guidelines (treatment-naive or treatment-experienced patients) (AASLD/IDSA 2015).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Oral capsule, oral solution (Rebetol, Ribasphere):</i></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">&lt;66 kg: 800 mg daily (400 mg in the morning and evening)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">66 to 80 kg: 1,000 mg daily (400 mg in the morning, 600 mg in the evening)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">81 to 105 kg: 1,200 mg daily (600 mg in the morning, 600 mg in the evening)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">&gt;105 kg: 1,400 mg daily (600 mg in the morning, 800 mg in the evening)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Duration of therapy: Manufacturer&rsquo;s labeling: Genotype 1: 48 weeks; Genotypes 2, 3: 24 weeks; patients who previously failed therapy: 48 weeks (regardless of genotype).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Chronic hepatitis C monoinfection (in combination with interferon alfa-2b):</b> <b>Note:</b> Nonpegylated interferons are <b>not</b> included in any recommended treatment regimens in HCV treatment guidelines (treatment-naive or treatment-experienced patients) (AASLD/IDSA 2015).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Oral capsule (Rebetol, Ribasphere):</i></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">&le;75 kg: 1,000 mg daily (400 mg in the morning, 600 mg in the evening)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">&gt;75 kg: 1,200 mg daily (600 mg in the morning, 600 mg in the evening)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Duration of therapy: Manufacturer&rsquo;s labeling: Individualized therapy duration of 24 to 48 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Chronic hepatitis C monoinfection (in combination with peginterferon alfa-2a): Note:</b> Combination therapy with peginterferon alone is not recommended in HCV treatment guidelines (treatment-naive or treatment-experienced patients) (AASLD/IDSA 2015).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Oral tablet (Copegus, Moderiba, Ribasphere):</i></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Genotype 1, 4:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">&lt;75 kg: 1,000 mg daily in 2 divided doses for 48 weeks</p>\n    <p style=\"text-indent:0em;margin-left:8em;\">&ge;75 kg: 1,200 mg daily in 2 divided doses for 48 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Genotype 2, 3: 800 mg daily in 2 divided doses for 24 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Chronic hepatitis C coinfection with HIV (in combination with peginterferon alfa-2a):</b> <i>Oral tablet (Copegus, Moderiba, Ribasphere):</i> 800 mg daily in 2 divided doses for 48 weeks (regardless of genotype). <b>Note:</b> Combination therapy with peginterferon alone is <b>not </b>recommended in clinical practice guidelines for HCV treatment treatment-naive or treatment-experienced patients, including those with HIV coinfection (AASLD/IDSA 2015).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">\n      <i>\n        <b>Alternate recommendations:</b></i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Chronic hepatitis C monoinfection (off-label regimens; AASLD/IDSA 2015):</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Weight-based ribavirin:</i></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">&lt;75 kg: 1,000 mg daily in 2 divided doses</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">&ge;75 kg: 1,200 mg daily in 2 divided doses</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Treatment regimens and durations are dependent on HCV genotype, treatment status (treatment-naive or treatment-experienced), as well as other factors (eg, presence of cirrhosis, interferon eligibility). Regimens presented are limited to those where ribavirin is a required component; regimens in which ribavirin use is optional have not been included; consult current AASLD/IDSA guidelines for further guidance:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <b>Treatment-naive patients:</b></p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Genotype 1a: Weight-based ribavirin in combination with dasabuvir and fixed dose paritaprevir/ritonavir/ombitasvir for 12 weeks (without cirrhosis) or 24 weeks (with cirrhosis)</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Genotype 2: Weight-based ribavirin in combination with sofosbuvir for 12 weeks (without cirrhosis) or 16 weeks (with cirrhosis)</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Genotype 3:</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">Weight-based ribavirin in combination with sofosbuvir and peginterferon (interferon-eligible patients) for 12 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">Weight-based ribavirin in combination with sofosbuvir (interferon-<b>ineligible</b> patients) for 24 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Genotype 4:</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">Weight-based ribavirin in combination with fixed dose paritaprevir/ritonavir/ombitasvir for 12 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">Weight-based ribavirin in combination with sofosbuvir for 24 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">Weight-based ribavirin in combination with sofosbuvir and peginterferon for 12 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Genotype 5 or 6: Weight-based ribavirin in combination with sofosbuvir and peginterferon for 12 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <b>Treatment-experienced patients:</b></p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Genotype 1a:</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">\n      <i>In whom a previous regimen of ribavirin and peginterferon has failed: </i>Weight-based ribavirin in combination with dasabuvir and fixed dose paritaprevir/ritonavir/ombitasvir for 12 weeks (without cirrhosis) or 24 weeks (with compensated cirrhosis)</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Genotype 1a or 1b:</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">\n      <i>In whom a previous regimen of ribavirin and peginterferon has failed: </i>Weight-based ribavirin in combination with ledipasvir/sofosbuvir for 12 weeks (with compensated cirrhosis)</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">\n      <i>In whom a previous sofosbuvir-containing regimen (with or without peginterferon) has failed: </i>Weight-based ribavirin in combination with ledipasvir/sofosbuvir for 12 weeks (without cirrhosis) or 24 weeks (with cirrhosis)</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">\n      <i>In whom a previous regimen of an HCV protease inhibitor (telaprevir, boceprevir, or simeprevir) plus ribavirin/peginterferon has failed: </i>Weight-based ribavirin in combination with ledipasvir/sofosbuvir for 12 weeks (with cirrhosis)</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Genotype 2:</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">\n      <i>In whom a previous regimen of ribavirin and peginterferon has failed:</i></p>\n    <p style=\"text-indent:-2em;margin-left:14em;\">Weight-based ribavirin in combination with sofosbuvir for 16 or 24 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:14em;\">Weight-based ribavirin in combination with sofosbuvir and peginterferon (interferon-eligible patients) for 12 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">\n      <i>In whom a previous regimen of sofosbuvir and ribavirin has failed: </i>Retreatment with weight-based ribavirin in combination with sofosbuvir and peginterferon (interferon-eligible patients) for 12 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Genotype 3:</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">\n      <i>In whom a previous regimen of ribavirin and peginterferon has failed:</i></p>\n    <p style=\"text-indent:-2em;margin-left:14em;\">Weight-based ribavirin in combination with sofosbuvir and peginterferon (interferon-eligible patients) for 12 weeks (with or without cirrhosis)</p>\n    <p style=\"text-indent:-2em;margin-left:14em;\">Weight-based ribavirin in combination with daclatasvir and sofosbuvir for 12 weeks (without cirrhosis) or 24 weeks (with cirrhosis; interferon-<b>ineligible</b> patients)</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">\n      <i>In whom a previous regimen of sofosbuvir and ribavirin has failed:</i></p>\n    <p style=\"text-indent:-2em;margin-left:14em;\">Weight-based ribavirin in combination with daclatasvir and sofosbuvir (interferon-<b>ineligible</b> patients) for 24 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:14em;\">Weight-based ribavirin in combination with sofosbuvir and peginterferon (interferon-eligible patients) for 12 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Genotype 4:</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">\n      <i>In whom a previous regimen of ribavirin and peginterferon has failed:</i></p>\n    <p style=\"text-indent:-2em;margin-left:14em;\">Weight-based ribavirin in combination with fixed dose paritaprevir/ritonavir/ombitasvir for 12 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:14em;\">Weight-based ribavirin in combination with sofosbuvir and peginterferon (interferon-eligible) for 12 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:14em;\">Weight-based ribavirin in combination with sofosbuvir for 24 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Genotype 5 or 6:</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">\n      <i>In whom prior treatment has failed: </i>Weight-based ribavirin in combination with sofosbuvir and peginterferon (interferon-eligible) for 12 weeks</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45623528\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=ribavirin-systemic-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Ribavirin (systemic): Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Chronic hepatitis C monoinfection (in combination with pegylated or nonpegylated interferon alfa-2b):</b> Manufacturer&rsquo;s labeling:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children &ge;3 years: <i>Oral capsule or solution (Rebetol, Ribasphere):</i> <b>Note:</b> Oral solution should be used in children &lt;47 kg, or those unable to swallow capsules. Children who start treatment prior to age 18 years  should continue on pediatric dosing regimen through therapy completion. Recommended therapy duration (manufacturer labeling): Genotypes 2, 3: 24 weeks; all other genotypes: 48 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Oral capsule, oral solution dosing recommendations:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">&lt;47 kg: 15 mg/kg/day in 2 divided doses (morning and evening) as oral solution</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">47 to 59 kg: 800 mg daily (400 mg in morning and evening)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">60 to 73 kg: 1,000 mg daily (400 mg in morning and 600 mg in the evening)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">&gt;73 kg: 1,200 mg daily (600 mg in morning and evening)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Chronic hepatitis C monoinfection (in combination with peginterferon alfa-2a):</b> Manufacturer&rsquo;s labeling:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children &ge;5 years and Adolescents: <i>Oral tablet (Copegus, Moderiba):</i> <b>Note:</b> Assess child&rsquo;s ability to swallow tablet; children who start treatment prior to age 18 years should continue on pediatric dosing regimen through therapy completion. Recommended therapy duration (manufacturer labeling): Genotypes 2, 3: 24 weeks; all other genotypes: 48 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">23 to 33 kg: 400 mg daily (200 mg in the morning and evening)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">34 to 46 kg: 600 mg daily (200 mg in the morning and 400 mg in the evening)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">47 to 59 kg: 800 mg daily (400 mg in the morning and evening)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">60 to 74 kg: 1,000 mg daily (400 mg in the morning and 600 mg in the evening)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">&ge;75 kg: 1,200 mg daily (600 mg in the morning and evening)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45623530\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45623531\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>CHC infection:</b> Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">Rebetol capsules/solution, Ribasphere capsules:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">Adults:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;text-align:justify;\">CrCl &ge;50 mL/minute: No dosage adjustments necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;text-align:justify;\">CrCl &lt;50 mL/minute: Use is contraindicated.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">Children: Serum creatinine &gt;2 mg/dL: Permanently discontinue treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">Ribasphere tablets: Adults:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">CrCl &ge;50 mL/minute: No dosage adjustments necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">CrCl &lt;50 mL/minute: Use is not recommended.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">Copegus and Moderiba tablets: Adults:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">CrCl &gt;50 mL/minute: No dosage adjustments necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">CrCl 30 to 50 mL/minute: Alternate 200 mg and 400 mg every other day.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">CrCl &lt;30 mL/minute: 200 mg once daily.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">ESRD requiring hemodialysis: 200 mg once daily.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">\n      <b>Note:</b> The dose of Copegus and Moderiba should not be further modified in patients with renal impairment. If severe adverse reactions or laboratory abnormalities develop it should be discontinued, if appropriate, until the adverse reactions resolve or decrease in severity. If abnormalities persist after restarting, therapy should be discontinued.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45623532\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">\n      <b>CHC infection:</b> Hepatic decompensation (Child-Pugh class B and C): Manufacturer&rsquo;s labeling: Oral tablets: Use contraindicated.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45623533\" class=\"block dot drugH1Div\"><span class=\"drugH1\">Dosing: Adjustment for Toxicity</span>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">\n      <b>Notes:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">Children and Adolescents: Once a laboratory abnormality or clinical adverse event has resolved, the ribavirin dose may be increased, based on clinical judgment, to its original assigned dose.  Initiate restart at 50% of the full dose.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">Adults: Once ribavirin has been withheld due to clinical adverse event or laboratory abnormality, an attempt can be made to restart ribavirin, in divided doses, at 600 mg daily, with a further ribavirin increase to 800 mg daily.  Increasing the ribavirin dose to its original assigned dose (1,000 to 1,200 mg daily) is not recommended.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">Patient <b>without</b> cardiac history:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Hemoglobin 8.5 to &lt;10 g/dL: </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Children &ge;3 years: Oral capsules, oral solution: </p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">First reduction: Decrease to 12 mg/kg/day</p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">Second reduction: Decrease to 8 mg/kg/day</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Children &ge;5 years and Adolescents: Oral tablets (Copegus, Moderiba): </p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">23 to 33 kg: Decrease dose to 200 mg daily (in the morning)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">34 to 59 kg: Decrease dose to 400 mg daily (200 mg in the morning and evening)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">&ge;60 kg: Decrease dose to 600 mg daily (200 mg in the morning and 400 mg in the evening)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Adults:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">Oral capsules, oral solution:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">First reduction:  &le;105 kg: Decrease by 200 mg daily; &gt;105 kg: Decrease by 400 mg daily</p>\n    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">Second reduction: Decrease by an additional 200 mg daily (not weight-based)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">Oral tablets: Decrease dose to 600 mg daily (200 mg in the morning, 400 mg in the evening)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Hemoglobin &lt;8.5 g/dL: Children, Adolescents, and Adults: Oral capsules, solution, tablets: Permanently discontinue treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">WBC &lt;1,000 mm<sup>3</sup>, neutrophils &lt;500 mm<sup>3</sup>: Children and Adults: Oral capsules, solution: Permanently discontinue treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Platelets &lt;50 x 10<sup>9</sup>/L: Children: Oral capsules, solution: Permanently discontinue treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Platelets &lt;25 x 10<sup>9</sup>/L: Adults: Oral capsules, solution: Permanently discontinue treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Laboratory abnormalities or adverse reactions other than decreased hemoglobin: Children &ge;5 years, Adolescents, and Adults: Oral tablets (Moderiba): Refer to dose modification guidelines in the manufacturer&rsquo;s labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">Patient <b>with</b> stable cardiac history: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Hemoglobin has decreased &ge;2 g/dL during any 4-week period of treatment: </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Children and Adolescents: Oral capsules, solution: Decrease ribavirin by 200 mg daily (regardless of the patient&rsquo;s initial dose); decrease peginterferon alfa-2b dose by 50%; monitor and evaluate weekly. If hemoglobin &lt;8.5 g/dL any time after dose reduction or &lt;12 g/dL after 4 weeks of dose reduction, permanently discontinue treatment. </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Children &ge;5 years and Adolescents: Oral tablets (Copegus, Moderiba): </p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">23 to 33 kg: Decrease dose to 200 mg daily (in the morning)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">34 to 59 kg: Decrease dose to 400 mg daily (200 mg in the morning and evening)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">&ge;60 kg: 600 mg daily (200 mg in the morning, 400 mg in the evening)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">\n      <b>Note:  </b>If hemoglobin &lt;8.5 g/dL any time after dose reduction or &lt;12 g/dL after 4 weeks of dose reduction, permanently discontinue treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Hemoglobin has decreased &ge;2 g/dL during any 4-week period of treatment: Adults:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Oral capsules, solution: Decrease dose by 200 mg daily; decrease peginterferon alfa-2b dose by 50%. If hemoglobin &lt;8.5 g/dL any time after dose reduction or &lt;12 g/dL after 4 weeks of dose reduction, permanently discontinue treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Oral tablets: Decrease dose to 600 mg daily (200 mg in the morning, 400 mg in the evening). If hemoglobin &lt;8.5 g/dL any time after dose reduction or &lt;12 g/dL after 4 weeks of dose reduction, permanently discontinue treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Hemoglobin &lt;8.5 g/dL: Children, Adolescents, and Adults: Oral capsules, solution, tablets: Permanently discontinue treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">WBC &lt;1,000 mm<sup>3</sup>, neutrophils &lt;500 mm<sup>3</sup>: Children and Adults: Oral capsules, solution: Permanently discontinue treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Platelets &lt;50 x 10<sup>9</sup>/L: Children: Oral capsules, solution: Permanently discontinue treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Platelets &lt;25 x 10<sup>9</sup>/L: Adults: Oral capsules, solution: Permanently discontinue treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Laboratory abnormalities or adverse reactions other than decreased hemoglobin: Children &ge;5 years, Adolescents, and Adults: Oral tablets (Moderiba): Refer to dose modification guidelines in the manufacturer&rsquo;s labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45623546\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Capsule, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Rebetol: 200 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Ribasphere: 200 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 200 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Rebetol: 40 mg/mL (100 mL) [contains propylene glycol, sodium benzoate; bubble-gum flavor]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Copegus: 200 mg [DSC]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Moderiba: 200 mg [contains fd&amp;c blue #2 aluminum lake]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Moderiba 1200 Dose Pack: 600 mg [contains fd&amp;c blue #1 aluminum lake]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Moderiba 800 Dose Pack: 400 mg [contains fd&amp;c blue #1 aluminum lake]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Ribasphere: 200 mg [contains fd&amp;c blue #2 aluminum lake]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Ribasphere: 400 mg, 600 mg [contains fd&amp;c blue #1 aluminum lake]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Ribasphere RibaPak: Ribasphere RibaPak 800: 400 mg AM dose, 400 mg PM dose, Ribasphere RibaPak 1200: 600 mg AM dose, 600 mg PM dose [contains fd&amp;c blue #1 aluminum lake]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">RibaTab: 400 mg [DSC], 600 mg [DSC] [contains fd&amp;c blue #1 aluminum lake]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 200 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet Therapy Pack, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Moderiba: 400 mg &amp; 600 mg (56 ea) [contains fd&amp;c blue #1 aluminum lake]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Moderiba: 200 mg &amp; 400 mg (56 ea) [contains fd&amp;c blue #1 aluminum lake, fd&amp;c blue #2 aluminum lake]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Ribasphere RibaPak: Ribasphere RibaPak 1000: 600 mg AM dose, 400 mg PM dose (14 ea, 56 ea) [contains fd&amp;c blue #1 aluminum lake]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Ribasphere RibaPak: Ribasphere RibaPak 600: 200 mg AM dose, 400 mg PM dose (14 ea, 56 ea) [contains fd&amp;c blue #1 aluminum lake, fd&amp;c blue #2 aluminum lake]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">RibaTab: 400 mg &amp; 600 mg (56 ea [DSC]) [contains fd&amp;c blue #1 aluminum lake]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45623476\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">May be product dependent</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45623469\" class=\"block meg drugH1Div\"><span class=\"drugH1\">Medication Guide and/or Vaccine Information Statement (VIS)</span>\n    <p style=\"text-indent:0em;display:inline\">An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">Copegus: <a target=\"_blank\" href=\"http://www.fda.gov/downloads/Drugs/DrugSafety/ucm088576.pdf&amp;token=SHauxSdf9qNc6lLK16E8IL3aNdSXbSTKjKzr5jWxn/9+evs591MjKrfB30zg8bRl5sCTY8iremx3rqidHKRndg==&amp;TOPIC_ID=105698\" target=\"_blank\">http://www.fda.gov/downloads/Drugs/DrugSafety/ucm088576.pdf</a></p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">Moderiba<a target=\"_blank\" href=\"http://dailymed.nlm.nih.gov/dailymed/medguide.cfm?setid=7046ff4c-8a75-5fd4-d40f-ff0cc84eed5f&amp;token=Ox8NWL1nw5Lc6xz8TuSKbf4N6AowF/alCKa//4yo7UiiN2zV8CL7z8z6A5fU0CsA0dLwzFmIuuiYBf6GDrB7mapUQwByGagryVMkGGwcclLl7k3m9f8+dSjDKy+DM7zQ&amp;TOPIC_ID=105698\" target=\"_blank\">http://dailymed.nlm.nih.gov/dailymed/medguide.cfm?setid=7046ff4c-8a75-5fd4-d40f-ff0cc84eed5f</a></p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">Rebetol: <a target=\"_blank\" href=\"http://www.fda.gov/downloads/Drugs/DrugSafety/ucm089017.pdf%20&amp;token=SHauxSdf9qNc6lLK16E8IL3aNdSXbSTKjKzr5jWxn/9+evs591MjKrfB30zg8bRlbX+CazZqRnnqDwsutGcTINAM2E3lciGdEloCfwEScok=&amp;TOPIC_ID=105698\" target=\"_blank\">http://www.fda.gov/downloads/Drugs/DrugSafety/ucm089017.pdf </a></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Ribasphere: http://kadmon.com/files/ribasphere-cap-pi.pdf</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45623535\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;margin-left:0em;text-align:justify;display:inline\">Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Capsule: Administer with food. Capsule should not be opened, crushed, chewed, or broken.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution: Administer with food.  Use oral solution for children &lt;47 kg, or those who cannot swallow capsules.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet: Administer with food.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49133432\" class=\"block hazard drugH1Div\"><span class=\"drugH1\">Hazardous Drugs Handling Considerations</span>\n    <p style=\"text-indent:0em;\">Hazardous agent (NIOSH 2016 [group 3]).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Use appropriate precautions for receiving, handling, administration, and disposal. Gloves (single) should be worn during receiving, unpacking, and placing in storage. NIOSH recommends single gloving for administration of intact tablets or capsules. NIOSH recommends double gloving, a protective gown, and (if there is a potential for vomit or spit up) eye/face protection for administration of an oral liquid/feeding tube administration (NIOSH 2016). Assess risk to determine appropriate containment strategy (USP-NF 2017).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45623482\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral capsule: In combination with interferon alfa 2b (pegylated or nonpegylated) injection for the treatment of chronic hepatitis C in interferon alfa-naive or experienced patients &ge;3 years of age with compensated liver disease. Patients likely to fail re-treatment after a prior failed course include previous nonresponders, those who received previous pegylated interferon treatment, patients who have significant bridging fibrosis or cirrhosis, or those with genotype 1 infection.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral solution: In combination with interferon alfa-2b (pegylated or nonpegylated) injection for the treatment of chronic hepatitis C in interferon alfa-naive or experienced patients &ge;3 years of age with compensated liver disease. Patients likely to fail re-treatment after a prior failed course include previous nonresponders, those who received previous pegylated interferon treatment, patients who have significant bridging fibrosis or cirrhosis, or those with genotype 1 infection.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral tablet: In combination with peginterferon alfa-2a for the treatment of adults (Copegus, Moderiba, Ribasphere) and patients &ge;5 years of age (Copegus and Moderiba) with chronic HCV infection who have compensated liver disease and have not previously been treated with interferon alpha, and in adult chronic hepatitis C patients coinfected with HIV</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>\n        <i>Guideline recommendations:</i></b> Peginterferon and ribavirin, <b>without</b> additional preferred HCV antiviral agent(s), is <b>not </b>recommended for hepatitis C virus (HCV) (regardless of genotype) in HCV adult treatment guidelines (treatment-naive or treatment-experienced). In addition, nonpegylated interferons are <b>not</b> included in any recommended HCV treatment regimens. Current AASLD/IDSA recommendations do not specify a particular peginterferon (eg, 2a or 2b) to combine with oral ribavirin and additional preferred HCV antiviral agent(s); however, guideline recommendations are based on clinical trials that used peginterferon alfa-2a (AASLD/IDSA 2015). Hepatitis C treatment guidelines are constantly changing with the advent of new treatment therapies and information; consult current clinical practice guidelines for the most recent treatment recommendations.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45623466\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Ribavirin may be confused with riboflavin, rifAMPin, Robaxin</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45623494\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">Clinical trials were conducted in patients receiving Peg Intron or Intron A, and it is not possible to correlate frequency of adverse events with ribavirin alone. Moreover, ribavirin monotherapy is not an effective treatment for chronic hepatitis.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Fatigue (63% to 68%; children and adolescents: 25% to 30%), headache (41% to 62%), rigors (25% to 48%), emotional lability (47%), irritability (25% to 47%; children and adolescents: 14% to 24%), anxiety (10% to 47%), chills (37% to 41%; children and adolescents: 21%), insomnia (30% to 41%), depression (&le;34%, severe), nervousness (33%), dizziness (13% to 21%), lack of concentration (10% to 21%), pain (9% to 13%), right upper quadrant pain (6% to 12%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Alopecia (17% to 36%), skin rash (8% to 34%), pruritus (15% to 29%), xeroderma (10% to 24%), dermatitis (16%), diaphoresis (6% to 11%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine and metabolic: Weight loss (children and adolescents: 10% to 43%; 10%), growth suppression (children and adolescents: 11% to 25%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Gastrointestinal disease (children and adolescents: 49%), nausea (25% to 43%, children and adolescents: 18%), anorexia (24% to 32%), vomiting (9% to 27%), decreased appetite (children and adolescents: 22%), diarrhea (11% to 22%), abdominal pain (8% to 21%), upper abdominal pain (children and adolescents: 12%), xerostomia (4% to 12%), liver decompensation (2% to 11%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic &amp; oncologic: Anemia (11% to 35%), neutropenia (14% to 33%), decreased platelet count (6% to 20%), lymphocytopenia (14%), hemolytic anemia (13%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infection: Viral infection (12%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Local: Injection site reaction (23% to 58%), erythema at injection site (children and adolescents: 29%), inflammation at injection site (18% to 25%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Weakness (63% to 66%; children and adolescents: 15%), myalgia (22% to 56%; children % adolescents: 17%), musculoskeletal pain (children and adolescents: 35%; 19% to 21%), arthralgia (17% to 34%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Flu-like symptoms (children and adolescents: 91%; 15% to 16%), dyspnea (13% to 26%), cough (10% to 23%), pharyngitis (12% to 13%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Miscellaneous: Fever (children and adolescents: 80%; 21% to 46%), drug tolerance (12%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Chest pain (5% to 9%), flushing (3% to 4%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Agitation (5% to 8%), memory impairment (6%), nervousness (6%), malaise (4% to 6%), mood changes (5%),</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Eczema (5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Menstrual disease (6% to 7%), hypothyroidism (4% to 5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Dyspepsia (6% to 9%), dysgeusia (4% to 9%), constipation (5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic &amp; oncologic: Leukopenia (5% to 10%), thrombocytopenia (2% to 5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hepatic: Hepatomegaly (4%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infecton: Fungal infection (1% to 6%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Back pain (5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Ophthalmic: Blurred vision (5% to 6%), conjunctivitis (4% to 5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Rhinitis (6% to 8%), sinusitis (5% to 6%), dyspnea on exertion (4%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Frequency not defined:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Cardiac disease, myocardial infarction</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Homicidal ideation, suicidal ideation</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Erythema multiforme, erythroderma, vesicobullous reaction</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Colitis, pancreatitis</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic &amp; oncologic: Bone marrow depression, pancytopenia, sarcoidosis</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hypersensitivity: Hypersensitivity reaction</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Immunologic: Exacerbation of sarcoidosis, autoimmune disease</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infection: Severe infection</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Pneumonia, pneumonitis, pulmonary complications, pulmonary infiltrates</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing and/or case reports: Aplastic anemia, auditory impairment, bacterial infection, dehydration, diabetes mellitus, graft rejection, hearing loss, pulmonary hypertension, pure red cell aplasia, relapse of drug dependence, retinal detachment, Stevens-Johnson syndrome, toxic epidermal necrolysis, vertigo</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45623491\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">Oral formulations: Hypersensitivity to ribavirin or any component of the formulation; women who are pregnant or may become pregnant; males whose female partners are pregnant; patients with hemoglobinopathies (eg, thalassemia major, sickle cell anemia); concomitant use with didanosine</p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">Ribasphere capsules and Rebetol capsules/solution: Additional contraindications: Patients with a CrCl &lt;50 mL/minute</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">Oral combination therapy with alfa interferons: Autoimmune hepatitis, hepatic decompensation (Child-Pugh score &gt;6; class B and C) in cirrhotic chronic hepatitis C monoinfected patients prior to treatment, hepatic decompensation (Child-Pugh score &ge;6) in cirrhotic chronic hepatitis C patients coinfected with HIV prior to treatment. Also refer to individual monographs for Interferon Alfa-2b (Intron A), Peginterferon Alfa-2b, and Peginterferon Alfa-2a (Pegasys) for additional contraindication information.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45623492\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hemolytic anemia: <b>[US Boxed Warning]: Hemolytic anemia is the primary clinical toxicity of oral therapy; anemia associated with ribavirin may worsen underlying cardiac disease and lead to fatal and nonfatal myocardial infarctions. Avoid use in patients with significant/unstable cardiac disease.</b> Anemia usually occurs within 1 to 2 weeks of therapy initiation; observed in ~10% to 13% of patients when alfa interferons were combined with ribavirin. Assess cardiac function before initiation of therapy. If patient has underlying cardiac disease, assess electrocardiogram prior to and periodically during treatment. If any deterioration in cardiovascular status occurs, discontinue therapy. Use caution in patients with baseline risk of severe anemia. Assess hemoglobin and hematocrit at baseline and, at minimum, weeks 2 and 4 of therapy since initial drop may be significant. Patients with renal dysfunction and/or those &gt;50 years of age should be carefully assessed for development of anemia.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic impairment: Risk of hepatic decompensation in chronic hepatitis C patients treated with combination therapy; monitor hepatic function closely and discontinue therapy immediately if evidence of hepatic decompensation is observed.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatitis C: Appropriate use: <b>[US Boxed Warning]: Ribavirin monotherapy is not effective for chronic hepatitis C infection and should not be used alone for hepatitis C.</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Use with caution in patients with renal impairment; dosage adjustment or discontinuation may be required.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Combination therapy with alfa interferons: </i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Autoimmune/infectious disorders: Have occurred with combination therapy; use with caution in patients with autoimmune disease or severe infection.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Bone marrow suppression: Pancytopenia has occurred with combination therapy and concomitant use of azathioprine; onset occurs within 3 to 7 weeks; discontinue combination therapy and azathioprine if pancytopenia occurs; may be reversible (usually within 4 to 6 weeks).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Dental and periodontal disorders: Have been reported with combination therapy; patients should be instructed to brush teeth twice daily and have regular dental exams. Xerostomia may contribute to and/or exacerbate dental disorders.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Dermatologic reactions: Severe cutaneous reactions, including Stevens-Johnson syndrome and exfoliative dermatitis have been reported (rarely) with combination therapy; discontinue immediately with signs or symptoms of severe skin reactions.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Diabetes: Has occurred with combination therapy; monitor blood sugars closely.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypersensitivity reactions: Acute hypersensitivity reactions (eg, anaphylaxis, angioedema, bronchoconstriction, and urticaria) have been observed with combination therapy; discontinue immediately with signs or symptoms of severe hypersensitivity reactions.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Ophthalmologic disorders: Serious disorders (eg, retinopathy, macular edema, retinal artery/vein thrombosis, optic neuritis, retinal detachment) have occurred with combination therapy. All patients require an eye exam at baseline; those with preexisting ophthalmologic disorders (eg, diabetic or hypertensive retinopathy) require periodic follow up. Discontinue therapy in patients with new or worsening ophthalmologic disorders.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pancreatitis: Has occurred with combination therapy; interrupt therapy if pancreatitis is suspected and discontinue if confirmed.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Psychiatric disorders: Severe psychiatric events have occurred including depression and suicidal/homicidal ideation during combination therapy. Suicidal ideation or attempts occurred more often in pediatric patients versus reports in adults during treatment and off-therapy follow-up (2.4% vs 1%). Avoid use in patients with a psychiatric history; discontinue if severe psychiatric symptoms occur.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pulmonary events: Pulmonary symptoms (eg, dyspnea, pulmonary infiltrates, pneumonitis, pneumonia [rarely fatal]) have been associated with combination therapy; use with caution in patients with pulmonary disease, including sarcoidosis (exacerbation reported).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Elderly: Use with caution in the elderly; may be more susceptible to adverse effects such as anemia. Monitor renal function closely.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pediatric: In combination therapy with alfa interferons, ribavirin may cause a reduction in growth velocity in pediatric patients for the length of treatment. Delay in weight and height increases have been noted in children treated with combination therapy. In clinical studies, decreases were noted in weight and height for age z-scores and normative growth curve percentiles. Following treatment, rebound growth and weight gain occurred in most patients; however, a small percentage did not. Long-term data indicate that combination therapy may inhibit growth resulting in reduced adult height. Growth should be closely monitored in pediatric patients during therapy and post-treatment for growth catch-up.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pregnancy: <b>[US Boxed Warning]: Significant teratogenic and/or embryocidal effects have been observed in all animal studies. Use is contraindicated in pregnant women or male partners of pregnant women. Avoid pregnancy in female patients and female partners of male patients during therapy by using two effective forms of contraception; continue contraceptive measures for at least 6 months after completion of therapy.</b> The manufacturer recommends that pregnant health care workers take precautions to limit exposure to ribavirin aerosol.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Benzyl alcohol and derivatives: Some dosage forms may contain sodium benzoate/benzoic acid; benzoic acid (benzoate) is a metabolite of benzyl alcohol; large amounts of benzyl alcohol (&ge;99 mg/kg/day) have been associated with a potentially fatal toxicity (&ldquo;gasping syndrome&rdquo;) in neonates; the &ldquo;gasping syndrome&rdquo; consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension, and cardiovascular collapse (AAP [&quot;Inactive&quot; 1997]; CDC 1982); some data suggests that benzoate displaces bilirubin from protein binding sites (Ahlfors 2001); avoid or use dosage forms containing benzyl alcohol derivative with caution in neonates. See manufacturer's labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: Safety and efficacy have not been established in patients who have failed previous interferon therapy, received organ transplants, or been coinfected with hepatitis B or HIV (ribavirin tablets may be used in adult HIV-coinfected patients with clinically stable disease and CD4+ cell count &gt;100 cells/mm<sup>3</sup>). Hemoglobin at initiation must be &ge;12 g/dL (women) or &ge;13 g/dL (men) in CHC monoinfected patients and &ge;11 g/dL (women) or &ge;12 g/dL (men) in CHC and HIV coinfected patients. Oral ribavirin should not be used for adenovirus, RSV, influenza or parainfluenza infections. Combination therapy of peginterferon and ribavirin, <b>without</b> additional HCV antiviral agent(s), is <b>not </b>recommended for the treatment of hepatitis C virus (AASLD/IDSA 2015).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45623501\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45623498\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=105698&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">AzaTHIOprine: Ribavirin (Systemic) may increase serum concentrations of the active metabolite(s) of AzaTHIOprine. Specifically, concentrations of potentially myelotoxic methylated metabolites may be increased, while concentrations of active 6-thioguanine nucleotides may be decreased.  Management: Consider using alternative agent(s) when possible.  When these drugs are used in combination, monitor patients closely for signs/symptoms of myelosuppression.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Didanosine: Ribavirin (Systemic) may enhance the adverse/toxic effect of Didanosine. Ribavirin (Systemic) may increase serum concentrations of the active metabolite(s) of Didanosine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Influenza Virus Vaccine (Live/Attenuated): Antiviral Agents (Influenza A and B) may diminish the therapeutic effect of Influenza Virus Vaccine (Live/Attenuated).  Management: Avoid anti-influenza antivirals during the period beginning 48 hours prior to and ending 2 weeks after vaccine administration.  Persons receiving these agents within 2 weeks of the live intranasal spray vaccine should receive a repeat vaccine dose.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Interferons (Alfa): May enhance the adverse/toxic effect of Ribavirin (Systemic). Hemolytic anemia has been observed.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vitamin K Antagonists (eg, warfarin): Ribavirin (Systemic) may diminish the anticoagulant effect of Vitamin K Antagonists. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Zidovudine: May enhance the adverse/toxic effect of Ribavirin (Systemic). Specifically, the risk/severity of anemia may be increased. Management: Due to significantly increased risk of anemia, consider even closer monitoring for anemia than routinely recommended for ribavirin. Alternative therapies should be considered when clinically possible, particularly for patients with other risk factors.<i> Risk D: Consider therapy modification</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45623506\" class=\"block foi drugH1Div\"><span class=\"drugH1\">Food Interactions</span>\n    <p style=\"text-indent:0em;display:inline\">High-fat meal increases the AUC and C<sub>max</sub>. Management: Capsule (in combination with peginterferon alfa-2b) and tablet should be administered with food. Other dosage forms and combinations should be taken consistently in regards to food.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45623487\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">X (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45623488\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>[US Boxed Warning]: Use is contraindicated in pregnant women or male partners of pregnant women. Significant teratogenic and/or embryocidal effects have been observed in all animal species with adequate studies. Avoid pregnancy in female patients and female partners of male patients during therapy by using two effective forms of contraception; continue contraceptive measures for at least 6 months after completion of therapy.</b> A negative pregnancy test is required immediately before initiation, monthly during therapy, and for 6 months after treatment is discontinued. If patient or female partner becomes pregnant during treatment, she should be counseled about potential risks of exposure.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Mother-to-child transmission of HCV does not occur if the woman is not viremic, therefore, HCV-infected women of childbearing potential should postpone pregnancy until therapy is complete. Treatment of HCV is not recommended for women who are already pregnant (AASLD/IDSA 2015).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Health care providers and patients are encouraged to enroll women exposed to ribavirin during pregnancy or within 6 months after treatment in the Ribavirin Pregnancy Registry (800-593-2214).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45623489\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if ribavirin is excreted in breast milk. Due to the potential for serious adverse reactions in the nursing infant, the manufacturer recommends that a decision be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of treatment to the mother.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45623534\" class=\"block dic drugH1Div\"><span class=\"drugH1\">Dietary Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Capsules, solution, and tablets should be taken with food.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45623538\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Manufacturer&rsquo;s labeling:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Pretreatment hematological and biochemical tests are recommended for all patients; dental exam, ECG (if preexisting cardiac abnormalities or disease) and ophthalmic exam (also periodically during treatment for those with preexisting ophthalmologic disorders) are also recommended. In adults, hematologic tests should be at treatment weeks 2 and 4, biochemical tests at week 4, and TSH at week 12. In pediatric patients, monitor growth closely during and after treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Pregnancy screening (in woman of childbearing age) and pregnancy tests monthly during and for 6 months after treatment discontinuation.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">In pediatric clinical studies, hematologic and biochemical assessments were made at weeks 1, 3, 5 and 8, then every 4 weeks thereafter. Growth velocity and weight should also be monitored during and periodically after treatment discontinuation.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Baseline values used in adult clinical trials in combination with alfa interferons:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Platelet count &ge;90,000/mm<sup>3</sup> (75,000/mm<sup>3</sup> for cirrhosis or 70,000/mm<sup>3</sup> for coinfection with HIV)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">ANC &ge;1,500/mm<sup>3</sup></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Hemoglobin &ge;12 g/dL for women and &ge;13 g/dL for men (11 g/dL for HIV coinfected women and 12 g/dL for HIV coinfected men)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">TSH and T<sub>4</sub> within normal limits or adequately controlled</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CD4<sup>+</sup> cell count &ge;200 cells/microL or CD4<sup>+</sup> cell count 100 to 200 cells/microL and HIV-1 RNA &lt;5,000 copies/mL for coinfection with HIV</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Serum HCV RNA (pretreatment, week 12 and week 24, and 24 weeks after completion of therapy).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Alternate recommendations (AASLD/IDSA 2015):</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Baseline (within 12 weeks prior to starting antiviral therapy): CBC, INR, hepatic function panel (albumin, total and direct bilirubin, ALT, AST, and alkaline phosphatase), calculated GFR</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Baseline (at any time prior to starting antiviral therapy): HCV genotype and subtype, quantitative HCV viral load</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">During therapy: CBC, serum creatinine, calculated GFR, hepatic function panel (after 4 weeks of therapy and as clinically indicated); quantitative HCV viral load testing (after 4 weeks of therapy and at 12 weeks after completion of therapy). If quantitative HCV viral load is detectable at treatment week 4, repeat testing is recommended after 2 additional weeks of treatment (treatment week 6).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45623513\" class=\"block rer drugH1Div\"><span class=\"drugH1\">Reference Range</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rapid virological response (RVR): Absence of detectable HCV RNA after 4 weeks of treatment</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Early viral response (EVR): &ge;2-log decrease in HCV RNA after 12 weeks of treatment</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">End of treatment response (ETR): Absence of detectable HCV RNA at end of the recommended treatment period</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sustained treatment response (STR) or sustained virologic response (SVR): Absence of HCV RNA in the serum 6 months following completion of full treatment course</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45623511\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Inhibits replication of RNA and DNA viruses; inhibits influenza virus RNA polymerase activity and inhibits the initiation and elongation of RNA fragments resulting in inhibition of viral protein synthesis</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45623514\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: Oral capsule: Single dose: V<sub>d</sub>: 2,825 L; distribution significantly prolonged in the erythrocyte (16 to 40 days), which can be used as a marker for intracellular metabolism</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding: Oral: None</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Hepatically and intracellularly (forms active metabolites); may be necessary for drug action</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Bioavailability: Oral: 64%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination, plasma: Adults: Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Capsule, single dose: 24 hours in healthy adults, 44 hours with chronic hepatitis C infection (increases to ~298 hours at steady state)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Tablet, single dose: ~120 to 170 hours </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak, serum: Oral capsule: Multiple doses: Children and Adolescents 3 to 16 years: ~2 hours; Adults: 3 hours; Tablet: 2 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Oral capsule: Urine (61%), feces (12%)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45623548\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsules</b> (Rebetol Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">200 mg (70): $741.74</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsules</b> (Ribasphere Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">200 mg (84): $394.13</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsules</b> (Ribavirin Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">200 mg (84): $800.19</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Rebetol Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">40 mg/mL (100 mL): $232.80</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablet Therapy Pack</b> (Moderiba Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">200 &amp; 400 mg (56): $876.55</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">400 &amp; 600 mg (56): $1,153.37</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablet Therapy Pack</b> (Ribasphere RibaPak Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">200 &amp; 400 mg (14): $427.32</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">400 &amp; 600 mg (14): $562.27</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Moderiba 1200 Dose Pack Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">600 mg (56): $1,384.02</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Moderiba 800 Dose Pack Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">400 mg (56): $922.68</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Moderiba Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">200 mg (168): $474.00</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Ribasphere Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">200 mg (168): $474.00</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">400 mg (56): $1,799.23</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">600 mg (56): $2,698.85</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Ribasphere RibaPak Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">400 mg (14): $449.81</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">600 mg (14): $674.71</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Ribavirin Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">200 mg (168): $1,390.00</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45855028\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Copeg (BD);</li>\n      <li>Copegus (AE, AR, AT, AU, BB, BE, BG, BH, CH, CL, CO, CY, CZ, DE, DK, EC, EE, ES, FI, FR, GB, GR, HK, HR, HU, IE, IL, IS, IT, JO, JP, KW, LB, LT, LU, LV, MX, MY, NL, NO, PL, PT, QA, RO, SA, SE, SG, SI, SK, TH, TR, UY, ZA);</li>\n      <li>Desiken (MX);</li>\n      <li>Hanavizin (VN);</li>\n      <li>Hepaviral (ID);</li>\n      <li>Ibavyr (AU, NZ);</li>\n      <li>Livel (UA);</li>\n      <li>Moderiba (DK, EE, FI, IE, LT, LV);</li>\n      <li>Opegus (BD);</li>\n      <li>Rebetol (AE, AT, AU, BB, BE, BH, BR, CH, CL, CO, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, ID, IE, IL, IN, IS, IT, JO, JP, LB, LT, MT, MY, NL, NO, NZ, PH, PL, PT, QA, RO, SE, SG, SI, SK, TR, VE, VN);</li>\n      <li>Riavirin (QA);</li>\n      <li>Ribacee (BD);</li>\n      <li>Ribarin (BD);</li>\n      <li>Ribavin (IN, LB);</li>\n      <li>Ribazole (VN);</li>\n      <li>Riboflax (CR, DO, GT, HN, NI, PA, SV);</li>\n      <li>Rui Di (CN);</li>\n      <li>Rybaryn (UA);</li>\n      <li>Trivorin (MX);</li>\n      <li>Varinar (MX);</li>\n      <li>Vilona (MX);</li>\n      <li>Virazide (CR, DO, GT, HN, ID, IN, MX, NI, PA, PK, SV);</li>\n      <li>Xilopar (AR);</li>\n      <li>Zyverin (LK)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    &lt;800&gt; Hazardous Drugs&mdash;Handling in Healthcare Settings. <i>United States Pharmacopeia and National Formulary</i> (USP 40-NF 35). Rockville, MD: United States Pharmacopeia Convention; 2017:83-102.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ahlfors CE. Benzyl alcohol, kernicterus, and unbound bilirubin. <i>J Pediatr</i>. 2001;139(2):317-319.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ribavirin-systemic-drug-information/abstract-text/11487763/pubmed\" target=\"_blank\" id=\"11487763\">11487763</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Academy of Pediatrics Committee on Infectious Diseases, &ldquo;Reassessment of the Indications for Ribavirin Therapy in Respiratory Syncytial Virus Infections,&rdquo; <i>Pediatrics</i>, 1996, 97(1):137-40.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ribavirin-systemic-drug-information/abstract-text/8545210/pubmed\" target=\"_blank\" id=\"8545210\">8545210</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    AASLD/IDSA. HCV Guidance: Recommendations for Testing, Managing, and Treating Hepatitis C. http://www.hcvguidelines.org/full-report-view. Updated 2015. Accessed September 16, 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control (CDC). Neonatal deaths associated with use of benzyl alcohol&mdash;United States. <i>MMWR Morb Mortal Wkly Rep</i>. 1982;31(22):290-291. <a href=\"http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm\" target=\"_blank\">http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm</a><span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ribavirin-systemic-drug-information/abstract-text/6810084/pubmed\" target=\"_blank\" id=\"6810084\">6810084</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Copegus (ribavirin) [prescribing information]. Nutley, NJ: Roche Laboratories; January 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Davis GL, Esteban-Mur R, Rustgi V, et al, &ldquo;Interferon Alfa-2b Alone or in Combination With Ribavirin for the Treatment of Relapse of Chronic Hepatitis C. International Hepatitis Interventional Therapy Group,&rdquo; <i>N Engl J Med</i>, 1998, 339(21):1493-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ribavirin-systemic-drug-information/abstract-text/9819447/pubmed\" target=\"_blank\" id=\"9819447\">9819447</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    DHHS Panel on Opportunistic Infections in HIV-Exposed and HIV-Infected Children. Guidelines for the Prevention and Treatment of Opportunistic Infections in HIV-Exposed and HIV-Infected Children. Department of Health and Human Services. November 2013. Available at <a href=\"http://aidsinfo.nih.gov/contentfiles/lvguidelines/oi_guidelines_pediatrics.pdf\" target=\"_blank\">http://aidsinfo.nih.gov/contentfiles/lvguidelines/oi_guidelines_pediatrics.pdf</a>.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    DHHS Panel on Opportunistic Infections in HIV-Infected Adults and Adolescents. Guidelines for the prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. October 2014. Available at <a href=\"http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf\" target=\"_blank\">http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf</a>. Accessed November 12, 2014</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dienstag JL and McHutchinson JG, &ldquo;American Gastroenterological Association Medical Position Statement on the Management of Hepatitis C,&rdquo; <i>Gastroenterology</i>, 2006, 130(1):225-30.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ribavirin-systemic-drug-information/abstract-text/16401485/pubmed\" target=\"_blank\" id=\"16401485\">16401485</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hoofnagle JH and Seeff LB,&rdquo;Peginterferon and Ribavirin for Chronic Hepatitis C,&rdquo; <i>N Engl J Med</i>, 2006, 355(23):2444-51.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ribavirin-systemic-drug-information/abstract-text/17151366/pubmed\" target=\"_blank\" id=\"17151366\">17151366</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    &quot;Inactive&quot; ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics (AAP) Committee on Drugs. <i>Pediatrics</i>. 1997;99(2):268-278.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ribavirin-systemic-drug-information/abstract-text/9024461/pubmed\" target=\"_blank\" id=\"9024461\">9024461</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lauer GM and Walker BD, &ldquo;Hepatitis C Virus Infection,&rdquo; <i>N Engl J Med</i>, 2001, 345(1):41-52.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ribavirin-systemic-drug-information/abstract-text/11439948/pubmed\" target=\"_blank\" id=\"11439948\">11439948</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    McHutchison JG, Gordon SC, Schiff ER, et al, &ldquo;Interferon Alfa-2b Alone or in Combination With Ribavirin as Initial Treatment for Chronic Hepatitis C. Hepatitis Interventional Therapy Group,&rdquo; <i>N Engl J Med</i>, 1998, 339(21):1485-92.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ribavirin-systemic-drug-information/abstract-text/9819446/pubmed\" target=\"_blank\" id=\"9819446\">9819446</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Moderiba (ribavirin) [prescribing information]. North Chicago, IL: AbbiVie Inc; December 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    &quot;PEDS-C: Pegylated Interferon +/- Ribavirin for Children With Hepatitis C,&quot; NCT0010065, updated November 2012. Available at <a href=\"http://clinicaltrials.gov/ct2/show/NCT00100659\" target=\"_blank\">http://clinicaltrials.gov/ct2/show/NCT00100659</a></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rebetol (ribavirin) capsules and oral solution [prescribing information]. Whitehouse Station, NJ: Merck &amp; Co, Inc; October 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ribasphere capsules (ribavirin) [prescribing information]. Warrendale, PA: Three Rivers Pharmaceuticals; January 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ribasphere tablets (ribavirin) [prescribing information]. Kenilworth, NJ: Schering Corporation; January 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Schwarz KB, Gonzalez-Peralta RP, Murray KF, et al, &ldquo;The Combination of Ribavirin and Peginterferon is Superior to Peginterferon and Placebo for Children and Adolescents With Chronic Hepatitis C,&rdquo; <i>Gastroenterology</i>, 2011, 140(2):450-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ribavirin-systemic-drug-information/abstract-text/21036173/pubmed\" target=\"_blank\" id=\"21036173\">21036173</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sokal E, Bourgois A, Stephenne X, et al, &ldquo;Peginterferon Alfa-2a Plus Ribavirin for Chronic Hepatitis C Virus Infection in Children and Adolescents,&rdquo; <i>J Hepatol</i>, 2010, 52(6):827-31.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ribavirin-systemic-drug-information/abstract-text/20400194/pubmed\" target=\"_blank\" id=\"20400194\">20400194</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href=\"http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf\" target=\"_blank\">http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf</a>. Updated September 2016. Accessed October 5, 2016.</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 105698 Version 57.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F45623465\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F45623473\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F45623474\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F45623478\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F45623529\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F45623528\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F45623530\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F45623531\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F45623532\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adjustment for Toxicity\" href=\"#F45623533\" class=\"outlineLink\">Dosing: Adjustment for Toxicity</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F45623546\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F45623476\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Medication Guide and/or Vaccine Information Statement (VIS)\" href=\"#F45623469\" class=\"outlineLink\">Medication Guide and/or Vaccine Information Statement (VIS)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F45623535\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Hazardous Drugs Handling Considerations\" href=\"#F49133432\" class=\"outlineLink\">Hazardous Drugs Handling Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F45623482\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F45623466\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F45623494\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F45623491\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F45623492\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F45623501\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F45623498\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Food Interactions\" href=\"#F45623506\" class=\"outlineLink\">Food Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F45623487\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F45623488\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F45623489\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Dietary Considerations\" href=\"#F45623534\" class=\"outlineLink\">Dietary Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F45623538\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Reference Range\" href=\"#F45623513\" class=\"outlineLink\">Reference Range</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F45623511\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F45623514\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F45623548\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F45855028\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/105698|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=ribavirin-systemic-patient-drug-information\" class=\"drug drug_patient\">Ribavirin (systemic): Patient drug information</a></li><li><a href=\"topic.htm?path=ribavirin-systemic-pediatric-drug-information\" class=\"drug drug_pediatric\">Ribavirin (systemic): Pediatric drug information</a></li></ul></div></div>","javascript":null}